Taizhou Crene Biotechnology Co., Ltd.
                                                                                                           
Verified Supplier
19 Years
Since 2007
Menu
Home Products VEGFR Inhibitors

VEGFR Inhibitors

China Regorafenib VEGFR Inhibitors for sale

Regorafenib VEGFR Inhibitors

Price: Negotiable
MOQ: 1g
Delivery Time: Negotiable

Chemical Information Product name:Regorafenib BAY 73-4506 Purity:98% min CAS NO:755037-03-7 Solubility:DMSO : ≥ 260 mg/mL (538.50 mM) Molecular Formula:C21H15ClF4N4O3 Package:Packaging according to customer requirements. Molecular Weight:482.82 Storage:Store at -20℃ Quality control COA Remarks Regorafenib, also known as BAY 73-4506 ; is an orally bioavailable small molecule with potential antiangiogenic and antineoplastic activities. Regorafenib binds to and inhibits vascular

China Sunitinib Malate VEGFR Inhibitors for sale

Sunitinib Malate VEGFR Inhibitors

Price: Negotiable
MOQ: 1g
Delivery Time: Negotiable

Chemical Information Product name:Sunitinib Malate Purity:99%min CAS NO:341031-54-7 Solubility:DMSO: 70 mg/mL (131.44 mM) Molecular Formula:C22H27FN4O2.C4H6O5 Package:Packaging according to customer requirements. Molecular Weight:532.56 Storage:Store at -20℃ Quality control COA Remarks Sunitinib, also known as SU11248, is the orally bioavailable malate salt of an indolinone-based tyrosine kinase inhibitor with potential antineoplastic activity. Sunitinib was approved by the

China Lenvatinib E7080 VEGFR Inhibitors for sale

Lenvatinib E7080 VEGFR Inhibitors

Price: Negotiable
MOQ: 1g
Delivery Time: Negotiable

Chemical Information Product name:Lenvatinib (E7080) Purity:99% min CAS NO:417716-92-8 Solubility:Soluble in DMSO Molecular Formula:C21H19ClN4O4 Package:Packaging according to customer requirements Molecular Weight:426.85 Storage:Store at -20℃ Quality control COA Remarks Lenvatinib (E7080) is a multi-target inhibitor, mostly for VEGFR2(KDR)/VEGFR3(Flt-4) with IC50 of 4 nM/5.2 nM, less potent against VEGFR1/Flt-1, ~10-fold more selective for VEGFR2/3 against FGFR1, PDGFRα/β in

1 2